Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elizabeth Zebrowski"'
Autor:
Ann W N Auma, Corinne Kowal, Carey L Shive, Alyssa Lange, Sofi Damjanovska, Elizabeth Zebrowski, Elane Reyes, Leonard Calabrese, Lenche Kostadinova, Yngve Falck-Ytter, Maya Mattar, Donald D Anthony
Publikováno v:
PLoS ONE, Vol 17, Iss 4, p e0267512 (2022)
BackgroundElevated rheumatoid factor (RF) levels and systemic immune activation are highly prevalent during chronic hepatitis C virus (HCV) infection. Direct-acting antiviral (DAA) therapy has been associated with normalization of various soluble imm
Externí odkaz:
https://doaj.org/article/ce466ae99a50403cb903760ee2886fb4
Autor:
Sofi Damjanovska, Hawwa Alao, Elizabeth Zebrowski, Corinne Kowal, Lenche Kostadinova, Perica Davitkov, Yngve Falck-Ytter, Carey L. Shive, Michael Cartwright, Brian Richardson, David Wald, Mark Cameron, Saba Valadkhan, Donald D. Anthony
Publikováno v:
Biology, Vol 11, Iss 9, p 1262 (2022)
Background: Hepatitis C virus (HCV) therapy lowers risk of hepatocellular carcinoma (HCC). Little is known about factors driving/preceding HCC in treated persons. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) regulate host response and pathog
Externí odkaz:
https://doaj.org/article/131cff5a4bf4481891dfcc198f640398
Autor:
Ann W.N. Auma, Carey L. Shive, Alyssa Lange, Sofi Damjanovska, Corinne Kowal, Elizabeth Zebrowski, Pushpa Pandiyan, Brigid Wilson, Robert C. Kalayjian, David H. Canaday, Donald D. Anthony
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundThe mechanisms underlying naïve CD4+ lymphopenia during chronic Hepatitis C Virus (HCV) infection are unclear. Whether direct-acting antiviral (DAA) therapy restores peripheral naïve CD4+ T cell numbers and function is unknown.MethodsWe e
Externí odkaz:
https://doaj.org/article/639e6fbfad364c11bc4487545f3d378e
Autor:
Lenche Kostadinova, Carey L. Shive, Elizabeth Zebrowski, Brianna Fuller, Kelsey Rife, Amy Hirsch, Anita Compan, Anita Moreland, Yngve Falck-Ytter, Daniel L. Popkin, Donald D. Anthony
Publikováno v:
Pathogens and Immunity, Vol 3, Iss 1, Pp 149-163 (2018)
Background: During chronic hepatitis C virus (HCV) infection, Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) levels mark active liver inflammation and tissue damage, while albumin reflects synthetic liver function and nutritional
Externí odkaz:
https://doaj.org/article/a651cb373a704c528bb45bc7a62bed87
Autor:
Kelsey Rife, Donald D. Anthony, Carey L. Shive, Xiaolin Li, Mark R. Chance, Chelsey J. Judge, Elizabeth Zebrowski, Daniela Schlatzer, Lenche Kostadinova, Daniel L. Popkin, Anita Compan, Amy Hirsch, Benigno Rodriguez, Yngve Falck-Ytter
Publikováno v:
Journal of Infectious Diseases. 214:1438-1448
BACKGROUND Immune activation predicts morbidity during hepatitis C virus (HCV) infection and human immunodeficiency virus (HIV) infection, although mechanisms underlying immune activation are unclear. Plasma levels of autotaxin and its enzymatic prod
Autor:
Ann Auma, Corinne Kowal, Elizabeth Zebrowski, Sofi Damjanovska, Carey Shive, Melissa Osborne, Robert Kalayjian, Donald D Anthony
Publikováno v:
The Journal of Immunology. 202:120.32-120.32
Background Chronic Hepatitis C virus (HCV), HCV/HIV and aging are known to predispose to impaired immunity to vaccines, new infections and cancers. Naïve CD4+CD31+ lymphopenia is exhibited in all three conditions, and may be one contributor to impai
Autor:
Dawid Krokowski, Raul Jobava, Maria Hatzoglou, Donald D. Anthony, Hiroto Kambara, Elizabeth Zebrowski, Saba Valadkhan, Lalith Gunawardane, Lenche Kostadinova
Publikováno v:
Frontiers in Immunology, Vol 5 (2015)
Frontiers in Immunology
Frontiers in Immunology
Recent genome-wide studies have revealed the presence of thousands of long non-protein-coding RNAs (lncRNAs), some of which may play critical roles in the cell. We have previously shown that a large number of lncRNAs show differential expression in r
Publikováno v:
The Journal of Immunology. 198:75.4-75.4
Background Natural Killer cells are thought to participate in control of HCV during the early phase of infection (first 6 months) and during IFN containing HCV therapy. At the same time, IFN resistance underlies wide variability in therapeutic respon